Sanofi (SNY) shares were up more than 1% Tuesday after the drugmaker said that Beyfortus for respiratory syncytial virus prevention in infants met both of its primary endpoints in its largest US real-world study.
The study showed that babies administered with Beyfortus were 87% less likely to develop RSV disease compared with babies who did not receive an injection of the antibody, the company said.
The study also showed that if babies who received Beyfortus later tested positive for RSV, they saw fewer overall medical visits during the illness, Sanofi said.
Beyfortus was developed in partnership with AstraZeneca (AZN). RSV is a contagious virus that can lead to respiratory illness, Sanofi said.
Price: 48.60, Change: +0.67, Percent Change: +1.40
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。